![Bruce F. Scharschmidt](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bruce F. Scharschmidt
Director/Board Member at PharmAkea, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Carl Torbjörn Bäckström | M | 76 |
Umecrine Cognition AB
![]() Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | 18 years |
Magnus Doverskog | M | - |
Umecrine Cognition AB
![]() Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | - |
Kevin Holme | M | - |
PharmAkea, Inc.
![]() PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | 12 years |
Thomas P. Blackburn | M | - |
Umecrine Cognition AB
![]() Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | 7 years |
Viktor Drvota | M | 59 |
Umecrine Cognition AB
![]() Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | 8 years |
Anders Eric Karlsson | M | 59 |
Umecrine Cognition AB
![]() Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | 2 years |
Mervyn Turner | M | 77 |
PharmAkea, Inc.
![]() PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | - |
Vanessa Lusitano Jacoby | F | - |
PharmAkea, Inc.
![]() PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | 12 years |
Christopher D. King | M | - |
PharmAkea, Inc.
![]() PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | - |
Rupert Vessey | M | 59 |
PharmAkea, Inc.
![]() PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | - |
John Öhd | M | 53 |
Umecrine Cognition AB
![]() Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | 4 years |
Andrew Tager | M | - |
PharmAkea, Inc.
![]() PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | - |
Hans Christopher Toll | M | 56 |
Umecrine Cognition AB
![]() Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | 3 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 7 | 53.85% |
United States | 6 | 46.15% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bruce F. Scharschmidt
- Personal Network